EP Patent

EP3777939A2 — Nasal delivery

Assigned to Optinose Inc · Expires 2021-02-17 · 5y expired

What this patent protects

A nosepiece for delivering substance to a nasal cavity of a subject, the nosepiece comprising a tip element which includes a delivery aperture from which substance is in use delivered into the nasal cavity, and the tip element is at least in part tapered so as to be inclined to a…

USPTO Abstract

A nosepiece for delivering substance to a nasal cavity of a subject, the nosepiece comprising a tip element which includes a delivery aperture from which substance is in use delivered into the nasal cavity, and the tip element is at least in part tapered so as to be inclined to a longitudinal axis of the nosepiece, with the delivery aperture extending both laterally across the tip element and along a longitudinal extent of the tip element.

Drugs covered by this patent

Patent Metadata

Patent number
EP3777939A2
Jurisdiction
EP
Classification
—
Expires
2021-02-17
Drug substance claim
No
Drug product claim
No
Assignee
Optinose Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.